A phase II study of irinotecan in patients with advanced hepatocellular carcinoma
Academic ArticleArticle
Overview
MeSH Major
Adenocarcinoma
Biomarkers, Tumor
Genomic Instability
Pancreatic Neoplasms
Precision Medicine
abstract
Irinotecan had modest activity in advanced hepatocellular cancer. Toxicity was substantial, presumably reflecting impaired underlying liver function or poor ability to metabolize and eliminate the drug. The current study indicated that continued new therapy assessment is warranted for this disease.
